栾鑫 研究员

　　   栾鑫  研究员

　　  上海中医药大学研究员、博士生导师

　　  交叉科学研究院中药系统药理学研究中心主任

　　  上海市中药化学生物学前沿研究基地副主任

　　  国家优秀青年基金获得者

　　  上海市曙光学者

      上海市东方学者特聘教授

　　  上海市青年科技启明星

　　  中华中医药学会青年托举人才

            基本信息丨招生专业丨教育及任职经历丨个人简介丨科研项目丨代表性文章

2007.9-2011.7    中国药科大学药学院                     学士

2011.9-2016.6    上海交通大学医学院                     博士

2015.9-2016.4    美国密西根大学药学院                 联合培养博士研究生

2016.7-2018.7    美国密西根大学药学院                 博士后研究员 

2018.8-2020.9   上海中医药大学交叉科学研究院    副研究员、硕士生导师

2020.10-至今     上海中医药大学交叉科学研究院    研究员、博士生导师、中心主任

个人简介与研究方向

长期聚焦中药来源抗肿瘤活性成分靶点发现及作用机制研究，建立了基于中药化学生物学和药理学技术的中药活性小分子靶标机制解析、天然活性多肽发现及创新应用等系列关键技术平台，从临床有效抗肿瘤中药出发，成功阐明鸦胆子苦素D、隐丹参酮、川楝素、蜂毒肽、鲎素等10余种中药来源抗肿瘤活性成分的直接靶标及作用机制。

先后主持国家自然科学基金优秀青年基金、面上项目、青年项目等科研项目10余项。以第一/通讯作者（含并列）身份在Trends Cancer，Adv Sci，Cell Rep Med，Trends Mol Med，Bioact Mater，Nat Prod Rep，APSB，Chem Eng J，Theranostics，JCI Insight，J Med Chem等期刊发表SCI论文60余篇，IF>10论文20余篇，引用4700余次，ESI高被引论文3篇。申请发明专利14项，授权6项，入选药学领域全球2%顶尖科学家榜单（World's Top 2% Scientist since 2023），获批I类新药临床试验批件1项。应邀担任Front Pharmacol, J Ethopharmacol，Chinese Medicine and Culture，Chinese Journal of Natural Medicine，中草药及中国药理学通报等多本期刊的编委；Adv Sci，APSB，Biomaterials，Small，Theranostics，J Med Chem等多本SCI杂志审稿人，参与编写人卫版十四五规划教材3部。目前兼任上海市药学会药理专委会副主任委员，中华中医药学会青年委员，中国药学会中药与天然药物专委会青年委员等。

代表性文章

1. Lin JY#, Wu Y#, Liang XH, Tang M, Sun X, Lu SX, Jin JM, Guo X, Wang B, Chen HZ*, Zhang WD*, Luan X*. A Self-Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple-Negative Breast Cancer Therapy. Adv Sci. 2025, e2500311. doi: 10.1002/advs.202500311. Online ahead of print. IF:14.3.

2. Lu S#, Zhang X#, Lin J, Liang R, Gong Y, Gao L, Cheng A, Lu X, Chen H, Wu Y *, Zhang W*, Luan X*. Diselenide bond-stapled β-hairpin peptide-loaded hydrogel system for boosting oncolytic immunotherapy. Chemical Engineering Journal. 2025,505:159076. doi.org/10.1016/j.cej.2024.159076. IF:13.4.

3. Liu Y#, Sun Q#, Guo J#, Yan L#, Yan Y, Gong Y, Lin J, Yuan H, Jin J, Wang B, Chen H, Zhang L*, Zhang W*, Luan X*. Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer. Cell Rep Med. 2025,6(1):101915. doi: 10.1016/j.xcrm.2024.101915. IF:11.7.

4. Ren M#, Sun X#, Lin J, Kan Y, Lu S, Zhang X, Liang R, Wang B, Chen H*, Wu Y*, Luan X*. Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy. J Control Release. 2025, 382:113717. doi: 10.1016/j.jconrel.2025.113717. Online ahead of print. IF:10.5.

5. Yan Y#, Gong Y#, Liang X#, Xiong Q, Lin J, Wu Y, Zhang L, Chen H*, Jin J*, Luan X*. Decoding β-catenin associated protein-protein interactions: Emerging cancer therapeutic opportunities. Biochim Biophys Acta Rev Cancer. 2025,1880(1):189232. doi: 10.1016/j.bbcan.2024.189232. IF:9.7.

6. Xia L, Guo X, Lu D, Jiang Y, Liang X, Shen Y, Lin J, Zhang L, Chen H, Jin J*, Luan X*, Zhang W*. S100A13-driven interaction between pancreatic adenocarcinoma cells and cancer-associated fibroblasts promotes tumor progression through calcium signaling. Cell Commun Signal. 2025, 23(1):51. doi: 10.1186/s12964-025-02049-7. IF:8.2.

7. Lu X*, Jin J*, Wu Y*, Lin J, Zhang X, Lu S, Zhang J, Zhang C, Ren M, Chen H*, Zhang W*, Luan X*. Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy. Bioact Mater. 2024,43:255-272. doi: 10.1016/j.bioactmat.2024.09.022. IF:18.0.

8. Gu WJ#, Liu XX#, Shen YW#, Gong YT, Chen YL, Lin J, Lu D, Zhang LJ, Chen HZ, Jin Y, Zhan ZJ*, Zhang WD*, Jin JM*, Luan X*. TRIM4 enhances small-molecule-induced neddylated-degradation of CORO1A for triple negative breast cancer therapy. Theranostics. 2024,14(18):7023-7041. doi: 10.7150/thno.97662. IF:12.4.

9. Bian HT#, Liang XH#, Lu D#, Lin JY, Lu XC, Jin JM, Zhang LY, Wu Y*, Chen HZ*, Zhang WD*, Luan X*. In Silico Discovery of Stapled Peptide Inhibitor Targeting the Nur77-PPARγInteraction and Its Anti-breast-cancer Efficacy. Adv Sci, 2024, 11(26):e2308435. doi: 10.1002/advs.2023084355. IF:14.3.

10. Zhang X#, Wu Y#, Lin J, Lu S, Lu X, Cheng A, Chen H*, Zhang W*, Luan X*. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges. Acta Pharm Sin B. 2024,14(9):3818-3833. doi: 10.1016/j.apsb.2024.05.013. IF:14.8.

11. Zhou H#, Shen Y#, Zheng G, Zhang B, Wang A, Zhang J, Hu H, Lin J, Liu S*, Luan X*, Zhang W*. Integrating single-cell and spatial analysis reveals MUC1-mediated cellular crosstalk in mucinous colorectal adenocarcinoma. Clin Transl Med. 2024,14(5):e1701. doi: 10.1002/ctm2.1701. IF:7.9.

12. Liang R, Cheng A, Lu S, Zhang X, Ren M, Lin J, Wu Y*, Zhang W*, Luan X*. Seleno-amino Acid Metabolism Reshapes the Tumor Microenvironment: from Cytotoxicity to Immunotherapy. Int J Biol Sci. 2024,20(7):2779-2789. doi: 10.7150/ijbs.95484. IF:8.2.

13. Luo XF#, Wu Y#, Zhang XK#, Tang M, Ju FY, Qin ZD, Duns GJ, Zhang WD*, Qin JJ*, Luan X*, Peptide-based strategies for overcoming multidrug-resistance in cancer therapy, Chin Chem Lett. 2024, doi: 10.1016/j.cclet.2024.109724. IF:9.1.

14. Wu Y#, Lin JY#, Zhou YD, Liu HJ, Lu SX, Zhang XK, Guan YY, Nagle DG, Zhang WD*, Chen HZ*, Luan X*. Oncolytic Peptide-Nanoplatform Drives Oncoimmune Response and Reverses Adenosine-Induced Immunosuppressive Tumor Microenvironment. Adv Healthc Mater. 2024, e2303445. doi: 10.1002/adhm.202303445. IF:10.0.

15. Lu X#, Jin JM#, Wu Y#, Liu X, Liang X, Lin J, Sun Q, Qin JJ*, Zhang W*, Luan X*. Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras. Med Res Rev. 2024, 44(2):812-832. IF:10.9.

16. Gong YT#, Zhang LJ#, Liu YC#, Tang M, Lin JY, Chen XY, Chen YX, Yan Y, Zhang WD*, Jin JM*, Luan X*. Neutrophils as potential therapeutic targets for breast cancer. Pharmacol Res. 2023, 198:106996. IF:9.1.

17. Lin JY, Liu HJ, Wu Y, Jin JM, Zhou YD, Zhang H, Nagle DG, Chen HZ*, Zhang WD*, Luan X*. Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer. Small, 2023, e2207778. IF:13.0.

18. Jin J#, Wu Y#, Zhao Z#, Wu Y, Zhou YD, Liu S, Sun Q, Yang G, Lin J, Nagle DG, Qin J, Zhang Z, Chen HZ, Zhang W*, Sun S*, Luan X*. Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer. JCI Insight, 2022, 7(22): e160606. IF:6.3.

19. Zheng X#, Zhang L#, Ju M, Liu L, Ma C, Huang Y, Wang B, Ding W, Luan X*, Shen B*. Rational Modulation of BODIPY Photosensitizers to Design Metal-Organic Framework-Based NIR Nanocomposites for High-Efficiency Photodynamic Therapy in a Hypoxic Environment. ACS Appl Mater Interfaces, 2022, 14(41):46262-46272. IF:8.5.

20. Bian HT#, Shen YW#, Zhou YD, Nagle DG, Guan YY*, Zhang WD*, Luan X*. CD47: Beyond an immune checkpoint in cancer treatment. Biochim Biophys Acta Rev Cancer, 2022. doi: 10.1016/j.bbcan.2022.188771. IF:9.7.

21. Lu L#, Zhang H#, Zhou YD, Lin JY, Gao WD, Yang T, Jin JM, Zhang LJ, Nagle DG, Zhang WD, Wu Y*, Chen HZ*, Luan X*. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer. Theranostics, 2022, 12(7):3456-3473. IF:12.4.

22. Huang R#, Zhang LJ#, Jin JM#, Zhou YD, Zhang HW, Lv C, Lu D, Wu Y, Zhang H, Liu SH, Chen HZ*, Luan X*, Zhang WD*. Bruceine D inhibits HIF-1a-mediated glucose metabolism in hepatocellular carcinoma by blocking ICAT/b-catenin interaction. Acta Pharm Sin B, 2021, 11(11):3481-3492. IF:14.8.

23. Lin JY#, Jin JM#, Shen YW#, Zhang LJ, Gong G, Bian HT, Chen HZ, Nagle DG, Wu Y*, Zhang WD*, Luan X*. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics, 2021, 11(17):8337-8349. IF:12.4.

24. Luan X#, Yuan H#, Song Y#, Hu H, Wen B, He M, Zhang H, Li Y, Li F, Shu P, Burnett JP, Truchan N, Palmisano M, Pai MP, Zhou S*, Gao W*, Sun D*. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation. Biomaterials, 2021, 275:120910. IF:12.8.

25. Wu Y#, Lu D#, Jiang YX, Jin JM, Liu SH, Chen LL, Zhang H, Zhou YD, Chen HZ, Nagle DG, Luan X*, Zhang WD*. Stapled Wasp Venom-Derived Oncolytic Peptides with Side Chains Induce Rapid Membrane Lysis and Prolonged Immune Responses in Melanoma. J Med Chem, 2021. 64(9):5802-5815. IF:6.9，封面论文。

26.Luan X#, Wu Y#, Shen YW, Zhang H, Zhou YD., Chen HZ, Nagle DG*, Zhang WD*. Cytotoxic and antitumor peptides as novel chemotherapeutics. Nat Prod Rep, 2021, 38(1):7-17. IF:10.2，封面论文。

27. Shen YW, Zhou YD, Chen HZ, Luan X*, Zhang WD*. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity. Trends Cancer, 2021, 7(6):511-524. IF:14.3.

28. Shen YW, Zhou YD, Luan X*, Zhang WD*. Blocking CTGF-Mediated Tumor-Stroma Interplay in Pancreatic Cancer. Trends Mol Med, 2020, 26(12):1064-1067. IF:12.8.

29. Huang R#, Shen YW#, Guan YY#, Jiang YX, Wu Y, Rahman K, Zhang LJ*, Liu HJ*, Luan X*. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology. Acta Biomater. 2020, 116: 1-15. IF:9.4.

30. Jin JM#, Wu Y#, Chen JJ, Shen YW, Zhang LJ, Zhang H, Chen LL, Yuan HB, Chen HZ, Zhang WD*, Luan X*. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics, 2020,10(22):10141-10153. IF:12.4，封面论文。

31. Luan X#, Guan YY#, Liu HJ, Lu Q, Zhao M, Sun D, Lovell JF, Sun P, Chen HZ*, Fang C*. A tumor vascular-targeted interlocking trimodal nanosystem that induces and exploits hypoxia. Adv Sci, 2018, 5(8): 1800034. IF:14.3，封面论文。

32. Luan X#, Sansanaphongpricha K#, Myers I, Chen H, Yuan H*, Sun D*. Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol Sin, 2017, 38(6):754-763. IF: 6.9，ESI高被引。

33. Luan X#, Guan YY#, Lovell JF, Zhao M, Lu Q, Liu YR, Liu HJ, Gao YG, Dong X, Yang SC, Zheng L, Sun P, Fang C*, Chen HZ*. Tumor Priming Using Metronomic Chemotherapy with Neovasculature-Targeted, Nanoparticulate Paclitaxel. Biomaterials, 2016, 95: 60-73. IF:12.8.

34. Guan YY#, Luan X#, Xu JR, Liu YR, Lu Q, Wang C, Liu HJ, Gao YG, Chen HZ*, Fang C*. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials, 2014, 35(9):3060-70. IF:12.8.